December 9, 2016
Patrik Jonsson, Chairman of PhRMA Japan-based Executive Committee A proposal to revise drug prices annually , which now looms as a real possibility, will demotivate drug makers to develop innovative drugs for Japan, and significantly erode the market’s attractiveness, Patrik...read more